| 4.69 0.34 (7.82%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.18 | 1-year : | 10.22 |
| Resists | First : | 7.01 | Second : | 8.75 |
| Pivot price | 6.62 |
|||
| Supports | First : | 4.2 | Second : | 3.49 |
| MAs | MA(5) : | 4.64 |
MA(20) : | 6.72 |
| MA(100) : | 6.44  |
MA(250) : | 4.31 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 9.5 |
D(3) : | 10.5 |
| RSI | RSI(14): 35.3 |
|||
| 52-week | High : | 9.27 | Low : | 1.43 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CPIX ] has closed above bottom band by 17.6%. Bollinger Bands are 171.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.77 - 4.79 | 4.79 - 4.82 |
| Low: | 4.3 - 4.34 | 4.34 - 4.37 |
| Close: | 4.64 - 4.69 | 4.69 - 4.74 |
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.
Tue, 27 Oct 2026
Cumberland Pharmaceuticals: The FDA's Phase 3 Question Is Hard To Ignore (NASDAQ:CPIX) - Seeking Alpha
Mon, 26 Oct 2026
Cumberland announces ifetroban NDA filing plan after shares plummet - Seeking Alpha
Mon, 26 Oct 2026
CPIX: Ifetroban’s Duchenne data support a planned NDA with FDA rolling review - TradingView
Sun, 25 Oct 2026
Cumberland Pharmaceuticals Inc. Estimates – NASDAQ:CPIX - TradingView
Fri, 23 Oct 2026
Cumberland Pharmaceuticals stock tumbles on trial results - Yahoo Finance UK
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 8.7e+006 (%) |
| Held by Institutions | 41.5 (%) |
| Shares Short | 275 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 1.1e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -24.7 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 898.6 % |
| Return on Equity (ttm) | -3 % |
| Qtrly Rev. Growth | 4.43e+007 % |
| Gross Profit (p.s.) | -1407.5 |
| Sales Per Share | -359.75 |
| EBITDA (p.s.) | 9.41e+008 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | 0 |
| PEG Ratio | 1.6 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.16 |
| Dividend | 0 |
| Forward Dividend | 348880 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|